Invokana dosage usually starts at 100 mg by mouth once daily before the morning meal for adults with type 2 diabetes who are prescribed canagliflozin. A prescriber may consider 300 mg once daily only when extra glucose lowering is needed, the 100 mg dose is tolerated, and kidney function supports the increase. This matters because renal function, dehydration risk, and other medicines can change both safety and expected benefit.
Key Takeaways
- Typical start: 100 mg once daily before the morning meal.
- Higher dose: 300 mg may fit only selected adults after review.
- Kidney checks: estimated glomerular filtration rate (eGFR) affects eligibility, dose limits, and monitoring.
- Illness planning: fasting, surgery, vomiting, or dehydration may require specific instructions.
- Safety watch: report infections, dizziness, foot wounds, or ketone symptoms promptly.
Invokana Dosage Basics: Strengths, Timing, and Titration
A safe Invokana dosage plan uses the lowest labeled dose that supports treatment goals while limiting avoidable risks. Invokana is the brand name for canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This drug class lowers blood glucose partly by helping the kidneys remove glucose through urine. For class context beyond this single medicine, see SGLT2 Inhibitors Explained.
Tablets are available in 100 mg and 300 mg strengths. Many adults start with 100 mg once daily. The labeled timing is before the first meal of the day, which often means before breakfast. A consistent routine helps reduce missed doses and makes side effects easier to track.
Canagliflozin is not a fast-acting correction medicine. It should not be used to treat a single high glucose reading or to replace insulin when insulin is required. If readings remain above target, the next step is a prescriber review of A1C, home glucose patterns, kidney labs, diet changes, and other medicines.
If a dose is missed
If a dose is missed, the usual label-based approach is to take it when remembered unless it is almost time for the next scheduled dose. Do not take two doses at once to make up for a missed tablet. If missed doses happen often, a medication routine, pill organizer, or phone reminder may help.
Higher Strength, Maximum Limits, and Decision Factors
A higher Invokana dosage is a targeted step, not the default. The maximum recommended dose is generally 300 mg once daily. Prescribers usually consider that strength only after confirming that 100 mg is tolerated and that more glucose lowering is still needed.
Kidney function is the main gatekeeper for the higher strength. In label-based dosing, the 300 mg dose is generally limited to adults with an eGFR of 60 mL/min/1.73 m² or higher. If kidney filtration is lower, the medicine may provide less glucose-lowering effect and may carry more risk. A1C trends also matter; for background on how this lab fits diabetes follow-up, see A1C in Type 2 Diabetes.
| Dosing situation | Common label-based point | Discussion to have |
|---|---|---|
| Starting treatment | 100 mg once daily is the usual starting dose. | Review hydration, blood pressure, kidney labs, and infection history. |
| Need more glucose lowering | 300 mg may be considered if 100 mg is tolerated and eGFR is high enough. | Discuss A1C targets, side effects, and current medicines. |
| eGFR 30 to less than 60 | The dose is typically capped at 100 mg once daily. | Clarify whether the goal is glucose control, kidney protection, or broader risk reduction. |
| eGFR below 30 | New starts are generally not recommended; some already treated patients with significant albuminuria may continue 100 mg under specialist direction. | Review benefit-risk, kidney care goals, and alternatives. |
| Dialysis | Use is contraindicated in patients on dialysis. | Plan a different diabetes regimen with the care team. |
This table is not a personal dosing schedule. Invokana dosage decisions should be revisited when labs change, new medicines are added, dehydration occurs, or side effects appear. Older adults and people taking water pills may need closer monitoring because fluid loss can have a stronger effect.
Kidney, Liver, and Illness Factors That Change the Plan
Kidney status is the main lab checkpoint before and during canagliflozin therapy. Clinicians commonly review eGFR, creatinine, electrolytes, blood pressure, and hydration. These values help determine whether the medicine remains appropriate and whether a dose increase is reasonable.
Liver disease can also affect the plan. Mild or moderate liver impairment may not require the same changes as kidney impairment, but severe hepatic impairment is a caution area because canagliflozin has not been studied enough in that group. If liver disease, heavy alcohol use, or recurrent dehydration is present, the prescriber may choose a more cautious approach.
Acute illness deserves special attention. Vomiting, diarrhea, fever, reduced food intake, or prolonged fasting can raise dehydration and ketone risk. The prescribing information also includes instructions to withhold canagliflozin before major surgery or procedures linked with prolonged fasting. The care team should explain when to pause and when it is safe to restart.
Why it matters: Ketone risk can rise during fasting, dehydration, infection, or sudden insulin reduction.
One serious concern is euglycemic ketoacidosis, which means dangerous blood acid buildup with glucose that may be only mildly elevated. Symptoms can include nausea, vomiting, stomach pain, unusual tiredness, shortness of breath, or confusion. For plain-language differences between nutritional ketosis and a medical emergency, see Ketosis vs Ketoacidosis.
Side Effects, Warning Signs, and Monitoring
Most routine side effects relate to fluid loss or higher glucose levels in urine. Increased urination, thirst, dizziness, genital yeast infections, urinary tract infections, nausea, and constipation can occur. These effects are not always dangerous, but they should be discussed if they persist, worsen, or lead to skipped doses.
Genital infections can occur in men and women. Prompt treatment helps reduce discomfort and may lower recurrence risk. Urinary symptoms such as burning, urgency, fever, flank pain, or blood in the urine should be reported, especially when symptoms suggest a kidney infection.
Some warnings are less common but more serious. Seek urgent care for symptoms of ketoacidosis, severe allergic reaction, fainting, severe dehydration, or intense pain, redness, swelling, or fever around the genital or perineal area. Rare cases of necrotizing fasciitis of the perineum, also called Fournier’s gangrene, have been reported with SGLT2 inhibitors.
Foot health also matters. Canagliflozin carries warnings related to lower-limb complications, and prescribers may be more cautious in people with prior amputation, peripheral vascular disease, neuropathy, or active foot ulcers. New sores, color changes, swelling, or pain in the feet should be checked promptly.
Home glucose readings can help show patterns, but they do not replace lab monitoring. If you track readings, use the plan your clinician gave you and compare results against individualized targets. For general number interpretation, see the Blood Sugar Range Chart.
Interactions and Combination Therapy
Other medicines can change the safety profile of canagliflozin. A medication review is especially important before dose increases, after hospital visits, or when a new prescription is added. Bring prescription drugs, over-the-counter products, and supplements to the discussion.
- Diuretics: fluid loss may increase dizziness, low blood pressure, or dehydration.
- Insulin or secretagogues: combination therapy may increase hypoglycemia (low blood sugar) risk.
- Blood pressure medicines: effects can add up when fluid volume falls.
- Enzyme-inducing drugs: some medicines may reduce canagliflozin exposure.
- Digoxin: monitoring may be needed when used together.
When metformin is part of the regimen, the two medicines work through different mechanisms. Canagliflozin increases urinary glucose loss, while metformin mainly reduces liver glucose production and improves insulin sensitivity. For a deeper comparison, see Invokana and Metformin.
Insulin or sulfonylurea doses should not be changed without clinician direction. Low readings, shaking, sweating, confusion, or repeated overnight lows should be reported. The prescriber may adjust the medicine most likely to cause hypoglycemia rather than changing every drug at once.
Some people use an SGLT2 inhibitor because heart or kidney risk also matters. Dosing still depends heavily on kidney function, tolerance, and the official label. For broader class context, see SGLT2 Heart and Kidney Care.
Monitoring, Access, and Practical Follow-Up
Monitoring turns a dose schedule into a safer routine. Ask which labs will be checked, which symptoms should trigger a call, and what to do during illness or fasting. Keep Invokana dosage questions in one list so the prescriber can address timing, kidney thresholds, missed doses, and side effects together.
Home tracking may include glucose readings, blood pressure, hydration cues, and infection symptoms. If your care team recommends devices or apps, choose tools you can use consistently. For a broader look at monitoring options, see Diabetes Tech.
Access logistics can affect adherence, but they should not drive unsupervised dose changes. Prescription referral services may confirm prescription details with the prescriber when required. Dispensing, where permitted, may be handled by licensed third-party pharmacies. Some patients also explore cash-pay options without insurance, depending on eligibility and jurisdiction.
If broader education helps, browse Type 2 Diabetes Resources for related topics on monitoring, medicines, and long-term risk reduction. Use those resources to prepare better questions, not to replace individualized care.
Authoritative Sources
Official medical guidance can change. The sources below support the dosing thresholds, safety warnings, and diabetes-care context discussed here.
- The U.S. Prescribing Information provides labeled canagliflozin dosing, renal thresholds, contraindications, interactions, and perioperative guidance.
- The ADA Standards of Care summarize professional recommendations for diabetes medication selection, monitoring, and complication risk reduction.
Recap
Canagliflozin dosing is simple on the surface but depends on important safety checks. The usual start is 100 mg once daily before the morning meal, while 300 mg is reserved for selected adults who tolerate treatment and meet kidney-function criteria. Illness, surgery, dehydration, infections, foot problems, and interacting medicines can all change the plan.
Use follow-up visits to review labs, symptoms, and glucose patterns. Never increase, stop, or restart canagliflozin without the instructions provided by your healthcare professional.
This content is for informational purposes only and is not a substitute for professional medical advice.
